CKD patients opt to stay on Dimerix drug after trial

Forty-five per cent of patients in Dimerix’s (ASX:DXB) successful Phase 2a trial in chronic kidney disease (CKD), on advice from their physician, applied for and were granted access to remain on DMX-200 under Australia’s Special Access Scheme, which allows participants continued access to a therapy after they complete a clinical study.

Read the complete story here